Most accessed

  • Published in last 1 year
  • In last 2 years
  • In last 3 years
  • All

Please wait a minute...
  • Select all
    |
  • Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 89-96. https://doi.org/10.13390/j.issn.1672-1861.2026.01.030
    Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary etiological factor for cervical intraepithelial neoplasia grade 2 (CIN 2). The accuracy of CIN 2 diagnosis is affected by the limitations of colposcopic biopsy and the variability in pathological interpretation. Underdiagnosis or overdiagnosis may lead to missed detection of more severe lesions or overtreatment. Particularly for young women and those with fertility requirement, overtreatment can increase the risk of adverse pregnancy outcomes in the future. Based on evidence-based medicine and China's national conditions, this consensus proposes refined management strategies for the CIN 2 women. Comprehensive consideration of multiple factors (including age, fertility needs, and lesion characteristics, etc) is required, for low-risk individuals eligible for conservative observation, close monitoring and dynamic assessment should be implemented. For high-risk individuals ineligible for conservative observation, it is recommended to undergo excisional treatment to reduce the risk of missed diagnosis and disease progression. For special populations of CIN 2: follow-up is the mainstay for pregnant women, with reassessment post-delivery; excisional treatment is preferred for postmenopausal women; and immunocompromised women require individualized assessment, enhanced monitoring, or active treatment.
  • Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 186-192.
    随着子宫颈癌筛查策略的优化,子宫颈鳞状上皮内病变,尤其是高级别鳞状上皮内病变(HSIL)的检出率显著上升,其临床管理面临治疗与保护生育功能的双重挑战。子宫颈切除性治疗和消融治疗虽能有效清除病灶,但不同程度的会增加术后流产、早产、子宫颈管狭窄等风险,影响生育结局。光动力治疗(PDT)作为一种非切除性、无创的治疗手段,通过选择性破坏病变细胞并清除高危型人乳头瘤病毒,实现清除病灶的同时,能最大限度地保留子宫颈正常结构和功能,为有生育需求的女性提供新的治疗选择。本共识基于现有循证医学证据,系统阐述了PDT的作用机制、不同光敏剂的应用特点、操作规范及适应证,旨在为不同级别子宫颈鳞状上皮内病变的临床规范化治疗提供指导。
  • Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 179-185. https://doi.org/10.13390/j.issn.1672-1861.2026.02.022
    高危型人乳头瘤病毒(HR-HPV)持续感染是导致子宫颈癌的主要病因,近年来,HPV核酸检测已逐渐成为子宫颈癌筛查的重要手段。随着对HPV基因型分布的深入研究和检测技术的不断进步,HR-HPV DNA载量(HR-HPV载量)作为一种反映疾病风险的重要指标,逐渐受到关注。当前研究显示,HR-HPV载量与病变的严重程度存在一定的相关性,同时,不同的检测技术也为其临床应用提供了多样化的选择。如何有效地基于HR-HPV载量进行风险分层和管理仍然面临诸多挑战,本专家共识阐述了HR-HPV载量与子宫颈上皮内病变和子宫颈癌的关系、HR-HPV载量的检测方法以及HR-HPV载量检测的临床应用,根据HR-HPV载量情况在子宫颈癌筛查和分流等方面提出推荐意见。
  • Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(4): 377-384. https://doi.org/10.13390/j.issn.1672-1861.2026.04.023
  • LI Mingzhu, ZHAO Yun, WEI Lihui.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 1-3. https://doi.org/10.13390/j.issn.1672-1861.2026.01.001
  • REN Qian, ZHANG Lijuan, XUE Yu, LU Danhua, WANG Weina, LIU Chunhong, WANG Yifei, FU Yuanyuan, SUN Yuefang, JI Guo, HUANG Qiongyi, ZHENG Jiayi, ZHU Huiting, SHAN Weiwei, CHEN Xiaojun
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 99-104. https://doi.org/10.13390/j.issn.1672-1861.2026.02.002
    Objective To explore the efficacy of fertility-preserving therapy (FST) in patients with POLE ultra-mutant (POLEmut) endometrial carcinoma (EC)/endometrial atypical hyperplasia (EAH), and to compare the therapeutic effects between theprogestogen/gonadotropin-releasing hormone agonist (GnRH-a) and immune checkpoint inhibitors (ICIs) regimens. Methods Clinical data of POLEmut EC/EAH patients who received FST were collected retrospectively at Obstetrics and Gynecology Hospital of Fudan University and Shanghai Tenth People's Hospital of Tongji University from April 2019 to November 2025. They were divided into progestogen/GnRH-a group (n=8) and ICIs group (n=5). Therapeutic, follow-up and pregnancy outcomes were compared between groups. Results Among the 13 patients, 7 cases underwent off-indication FST, and 5 cases in the ICIs group were off-indication. There was no significant difference in the complete response (CR) rate between the two groups (P=1.000). The median CR time in the ICIs group (28.2 weeks) was shorter than that in the progestogen/GnRH-a group (35.9 weeks, P=0.450). There were 4 refractory cases, including 3 in the progestogen/GnRH-a group and 1 case in the ICIs group, with no statistical difference (P=1.000). The median total follow-up time and post-CR follow-up time in the ICIs group were significantly shorter than those in the progestogen/GnRH-a group (median 21.1 months vs 44.6 months, 14.0 months vs 33.8 months, both P<0.05). No recurrence was observed in the ICIs group, while 2 cases of recurred were in the progestogen/GnRH-a group (P=0.467). Among the 8 CR patients, 7 achieved successful pregnancy, including 5 cases in the progesterone/GnRH-a group, all of which resulted in successful pregnancies with 4 live births; 2 cases in the ICIs group achieved successful pregnancy, both of which were in the third trimester. Conclusion Both progestogen/GnRH-a and ICIs regimens are effective for FST in POLEmut EC/EAH patients. With all ICIs patients undergoing off-indication FST, the ICIs regimen shows a trend of faster onset, better short-term disease control and favorable pregnancy outcomes, which may be a preferred FST option.
  • LEI Jieyun, LI Jianfang, ZHANG Li, XU Yingying, WANG Yanzhou.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 119-123. https://doi.org/10.13390/j.issn.1672-1861.2026.02.006
    Objective To explore the clinical effect of niraparib combined with bevacizumab in the treatment of BRCA1/2 wild-type homologous recombination defect (HRD)-negative advanced ovarian cancer. Methods A retrospective analysis study design was used. The clinical data of 98 patients with BRCA1/2 wild-type and HRD-negative advanced ovarian cancer admitted to the First Affiliated Hospital of Army Medical University were collected from January 2022 to December 2024. 58 patients who received maintenance treatment with bevacizumab alone were set as control group, and 40 patients who received maintenance treatment with niraparib combined with bevacizumab were set as observation group. The progression-free survival (PFS), toxicity reactions and blood test indexes were analyzed. Results The median progression-free survival of patients in study group was 24 months and that in control group was 20 months, revealing a significant difference between two groups (P=0.002). After treatment, the levels of serum carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), B-cell lymphoma-2 (Bcl-2) and Bcl-2 binding anti-apoptotic gene-1 (Bag-1), translocators protein (TSPO) and cell-free mitochondrial DNA (cf-mtDNA) and levels of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), interleukin-1β (IL-1β) and cysteine protease 1 (Caspase-1) in peripheral blood mononuclear cells in study group were lower than those in control group (P<0.05). The level of serum Bcl-2 related X protein (Bax) was higher in study group than that in control group (P<0.05). The toxicity reactions in both groups were mainly mild-to-moderate systemic reactions, digestive system toxicity and cardiovascular system toxicity, with no significant differences between groups (P>0.05). Conclusions Niraparib combined with bevacizumab for first-line maintenance treatment of BRCA1/2 wild-type HRD-negative advanced ovarian cancer can prolong the progression-free survival of patients. Its possible mechanism is to exert anti-tumor effects by improving the imbalance of cell apoptosis and relieving inflammatory responses, and its safety is controllable.
  • WNAG Xiaoqin, WANG Hui, XU Zhengjun, ZHANG Changhong, WANG Changhong.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 7-10. https://doi.org/10.13390/j.issn.1672-1861.2026.01.003
    Objective To investigate the relationship between non-16/18 high-risk human papillomavirus (HPV) infection and cervical precancerous lesions. Methods A retrospective study was conducted on 1 154 patients who were positive for non-16/18 high-risk HPV and negative for liquid-based thin-layer cytology test (TCT) at Fuyang People's Hospital from January 2020 to October 2024. All patients underwent colposcopic cervical biopsy. The correlations between infection type, HPV subtype, age, and pathological results were analyzed. Results Among the patients, 861 cases (74.61%) had single-type infection, and 293 cases (25.39%) had mixed-type infection. The detection rate of mixed high-risk HPV cases was significantly higher than that of mixed high-and low-risk HPV cases (18.72% vs 6.67%, P<0.05). Pathological results showed that the detection rates of <low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and squamous cell carcinoma (SCC) were 74.44%, 13.86%, 11.61%, and 0.09% respectively. The detection rate of HSIL in patients with mixed-type infection was significantly higher than that in patients with single-type infection (17.75% vs 9.52%, P<0.05). The top 8 subtypes of single-type infection were HPV 52, 58, 53, 68, 31, 39, 56, and 33 in sequence. The subtypes mainly associated with LSIL were HPV 68, 58, and 59, while those mainly associated with HSIL were HPV 68, 58, and 52. Significant differences were observed in HPV subtypes 33, 52, 59, and 68 between LSIL and HSIL groups (P<0.05). In terms of age distribution, patients aged 35~44 years accounted for the highest proportion (32.32%), and patients aged ≥65 years had the highest detection rate of precancerous lesions (42.86%). The detection rate of HSIL increased with the increase in age groups. Conclusions Patients with non-16/18 high-risk HPV infection still have a relatively high risk of lesions above HSIL. For cases with non-16/18 high-risk HPV infection and negative TCT results, it is still necessary to perform a colposcopic cervical biopsy.
  • WANG Chen, LIU Yan, WANG Yuxiang, YANG Jing, ZHAO Xiaoya, SONG Zixiu, LIU Congrong.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 129-133. https://doi.org/10.13390/j.issn.1672-1861.2026.02.008
    Objective Based on the 2020 WHO classification of female genital tumors, this study aims to systematically compare the differences in clinicopathological and molecular characteristics between ovarian endometrioid carcinoma (OEC) and ovarian clear cell carcinoma (OCCC). Methods Clinicopathological data from 268 OEC cases and 120 OCCC cases were collected. Molecular subtyping data were obtained for 124 OEC and 41 OCCC cases. Targeted sequencing was performed on 91 OEC and 19 OCCC cases. Results ① Compared to OCCC patients, OEC patients were younger, had smaller tumors, and a higher rate of bilateral ovarian involvement. They underwent comprehensive staging surgery and chemotherapy at lower rates, and exhibited higher positive immunohistochemical expression rates of ER, PR, and WT1 (all P<0.001). ② The prognosis of OEC was significantly better than that of OCCC patients. Histological grade showed a significant negative correlation with progression free survival (PFS) of OEC patients (HR=3.9, P=0.032). ③ The WHO molecular classification had prognostic stratification significance for overall survival (OS) in OEC patients (P=0.041). ④ High-frequency mutations in OEC were concentrated in the RAF-MEK-ERK, PI3K-AKT-mTOR, and Wnt/β-catenin signaling pathways, whereas OCCC mutations were mainly found in the PI3K-AKT-mTOR and chromatin remodeling signaling pathways. Conclusions OEC and OCCC exhibit significant differences in clinicopathological characteristics and core molecular pathways. OCCC, grade 3 OEC, and the p53abn subtype of OEC should all be considered high-risk subtypes, and it is recommended that they receive heightened attention and intensified intervention in clinical management.
  • HE Yijiao, LI He, MENG Meng, TANG Xiaoge, LIU Yuanyuan, WANG Jianliu, DONG Yangyang.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 115-118. https://doi.org/10.13390/j.issn.1672-1861.2026.02.005
    Objective To investigate the clinical efficacy of molecular classification-guided fertility-sparing treatment in patients with endometrial carcinoma (EC). Methods Clinical data of 88 EC patients who received fertility-sparing treatment at Peking University People's Hospital from January 2023 to June 2025 were retrospectively analyzed. Among them, 64 cases were of no specific molecular profile (NSMP) type, 10 cases mismatch repair deficient (MMRd) type, 8 cases p53 abnormal (p53abn) type, and 6 cases POLE type. Results ① All 6 patients with POLE-type EC achieved complete remission (CR), with a median CR time of 8.5 months (3 months, 20 months), but 2 cases relapsed. The CR rate of NSMP-type patients was 76.56% (49/64), with a median CR time of 9 months (3 months, 27 months). ② Among the 10 MMRd-type EC patients, 9 achieved CR, and 8 of them achieved CR through progesterone combined with immunotherapy. ③ Among the 8 patients with p53abn type EC who received individualized progesterone therapy±chemotherapy, the median CR time was 8 months (3 months, 22 months), and 1 case relapsed 3 months after treatment. Conclusions Molecular typing can precisely guide the treatment and prognosis of EC patients. The POLE type treatment for preserving fertility has a high rate of CR, but the recurrence rate is also high. The NSMP type patients exhibit significant heterogeneity and have a relatively low CR rate. It is imperative to further stratify NSMP for more precise treatment. Patients with MRRd type can benefit from combined immunotherapy. Although patients with p53abn type have a high risk of progression and recurrence, CR can still be achieved after careful assessment and individualized treatment.
  • XIAO Zerui, WANG Yiqin, SONG Ziyi, SONG Jingrong, WANG Jianliu, LU Qun, TIAN Li
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 105-109. https://doi.org/10.13390/j.issn.1672-1861.2026.02.003
    Objective To investigate the disease recurrence risk, pregnancy outcomes, and influencing factors in patients with endometrial carcinoma (EC) or atypical endometrial hyperplasia (AEH) undergoing in vitro fertilization and embryo transfer (IVF-ET) after achieving complete response (CR) following fertility-sparing treatment (FST). Methods This multicenter retrospective cohort study included 109 patients with a history of EC or AEH who underwent IVF-ET at the reproductive centers of Peking University People's Hospital and Beijing Chaoyang Hospital from January 2009 to January 2024. Based on recurrence during follow-up, patients were divided into a recurrence group (n=28) and a non-recurrence group (n=81). A Cox regression model was used to analyze independent factors affecting recurrence. Pregnancy outcomes were also analyzed for patients who underwent embryo transfer. Results The proportion of EC patients was significantly higher in the recurrence group than in the non-recurrence group (53.6% vs. 32.1%, P=0.043). Multivariate analysis identified initial pathological type (EC), a longer interval from discontinuation of high-dose progestin to the start of controlled ovarian hyperstimulation (COH), and a higher cumulative estradiol (E2) level during COH cycles as independent risk factors for recurrence (all P<0.05). Among the 98 patients who underwent embryo transfer, the cumulative ongoing pregnancy rate was 55.1% (54/98), and the cumulative live birth rate was 43.9% (43/98). In 203 transfer cycles, the endometrial thickness was significantly greater in the cycles achieving ongoing pregnancy than in those that did not (P=0.012). Conclusions Initial pathological type EC, a prolonged interval to assisted reproduction, and high E2 exposure during COH may be associated with an increased recurrence risk in AEH/EC patients after FST. These patients can achieve certain pregnancy opportunities through assisted reproductive technology (ART), and endometrial thickness may be one of the factors influencing pregnancy outcomes. Clinical practice should involve a comprehensive assessment of recurrence risk and reproductive potential to aid in formulating more individualized fertility treatment strategies.
  • WANG Na, WANG Yiqin, CHENG Jin, ZHANG Xiaobo, HE Yijiao, WANG Yi, SHEN Danhua, WANG Jianliu.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 110-114. https://doi.org/10.13390/j.issn.1672-1861.2026.02.004
    Objective To analyze the oncological and fertility outcomes of fertility-preserving treatment in stageⅠG1 endometrial cancer patients with and without myometrial invasion (MI). Methods This single-center retrospective study at Peking University People's Hospital included 63 patients from June 2010 to December 2022. Among them, 17 had superficial MI, 4 cases had deep MI, and 42 had no MI. MI depth was assessed by magnetic resonance imaging (MRI), and treatment response was evaluated via hysteroscopy directed biopsy combined with ultrasound and (or) MRI. Primary outcomes were complete response (CR) rate, recurrence rate, and disease-free survival (DFS). Results 59/63 patients (93.65%) achieved CR with a median time of 7 (3~14) months. Recurrence occurred in 13/59 patients (22.03%) within a median of 19 (10~43.5) months. Patients with MI had a larger tumor size (3.6 cm vs 2.6 cm, P=0.003) and a slightly higher rate of adenomyosis (28.57% vs 11.90%, P=0.100). There were no significant differences in treatment response and fertility outcomes (P>0.05). Both MI depth and tumor size could moderately predicted recurrence. The recurrence rate seemed higher in MI patients (33.33% vs 15.79%, P=0.196). Patients with deep MI had significantly shorter DFS (P=0.036), while those with MI depth below 2.5 mm (P=0.106) and without adenomyosis (P=0.081) tended to have longer DFS. Conclusions While the depth of MI is associated with recurrence rate and DFS, fertility-sparing treatment remains a viable option for carefully selected patients with MI.
  • LIU Peng, HAN Senji, SUN Yi.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(3): 200-203. https://doi.org/10.13390/j.issn.1672-1861.2026.03.003
    Objective To explore expressions and clinical significance of serum placental growth factor (PlGF), soluble Fms-like tyrosine kinase-1 (sFlt-1) and sFlt-1/PlGF in pregnant women with early-onset severe preeclampsia (EOSPE). Methods A total of 91 patients with EOSPE admitted to Zibo First Hospital were enrolled as observation group between June 2020 and June 2024, while 91 normal pregnant women undergoing cesarean section during the same period were enrolled as control group according to the principle of propensity matching. The levels of serum PlGF and sFlt-1, and sFlt-1/PlGF were compared between the two groups, and their relationship with blood pressure (SBP, DBP) and umbilical artery flow parameters [peak systolic velocity/end diastolic velocity (S/D), pulsatility index (PI), resistance index (RI)] was analyzed. The predictive value of serum PlGF, sFlt-1 and sFlt-1/PlGF in adverse pregnancy outcomes in EOSPE patients was evaluated by ROC curves. Results Compared with control group, level of serum PlGF was lower in observation group, sFlt-1 level and sFlt-1/PlGF were higher, SBP, DBP and S/D were higher (P<0.05). The level of serum PlGF was negatively correlated with SBP, DBP and S/D (P<0.05), while sFlt-1 level and sFlt-1/PlGF were positively correlated with them (P<0.05). Compared with good pregnancy outcome group, level of serum PlGF was lower, while sFlt-1 and sFlt-1/PlGF were higher in adverse pregnancy outcome group. ROC curves analysis showed that AUC values of serum PlGF, sFlt-1 and sFlt-1/PlGF for predicting adverse pregnancy outcomes in EOSPE patients were 0.822, 0.862 and 0.907, showing high diagnostic value (P<0.05). AUC of sFlt-1/PlGF was higher (P<0.05). Conclusion The decrease of serum PlGF and increase of sFlt-1 and sFlt-1/PlGF are correlated with disease progression in EOSPE patients, and sFlt-1/PlGF has certain predictive value in adverse pregnancy outcomes.
  • LIN Ping, CHEN Huan, WANG Jing, LI Rui, ZHAO Ning.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 4-6. https://doi.org/10.13390/j.issn.1672-1861.2026.01.002
    Objective To analyze the influencing factors of cervical canal adhesion in patients with high-grade squamous intraepithelial lesion (HSIL) after loop electrosurgical excision procedure (LEEP). Methods The clinical data of 106 patients with HSIL who received LEEP treatment in Hengshui People's Hospital from January 2022 to December 2024 were retrospectively collected. The follow-up data were reviewed. According to the occurrence of cervical canal adhesion after the operation, they were divided into the adhesion group (n=23) and the non-adhesion group (n=83). Clinical data, including follow-up records, were collected via the hospital's electronic medical record system to analyze risk factors for cervical adhesion after LEEP. Results The adhesion group had greater age, intraoperative blood loss, and resection depth, and higher rates of wound infection, premature sexual activity, and vaginal dysbiosis than the non-adhesion group (P<0.05). Multivariate Logistic regression analysis showed that intraoperative bleeding volume, resection depth, wound infection, premature sexual activity, and vaginal microbiota imbalance were the influencing factors for cervical canal adhesion after LEEP in HSIL patients (P<0.05). Conclusions Intraoperative bleeding volume, resection depth, wound infection, premature sexual activity, and vaginal microbiota imbalance are influencing factors for cervical canal adhesion after LEEP in HISL patients.
  • ZHANG Yang, LI Shuangshuang, LI He, ZHANG Hui, WANG Yue, YANG Feng, LI Xiaoping
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 134-137. https://doi.org/10.13390/j.issn.1672-1861.2026.02.009
    Objective To investigate the clinical characteristics, diagnostic and therapeutic approaches, and prognostic factors in patients with pulmonary metastases from Uterine malignant tumor. Methods A retrospective analysis was conducted of 35 patients with pulmonary metastases from Uterine malignant tumor admitted to Peking University People's Hospital between January 2010 and January 2024. Clinical features, diagnostic and therapeutic processes, follow-up, and prognostic factors were reviewed. Results The mean age of the 35 patients was (56.5±10.1) years, including 28 cases of endometrial carcinoma, 6 cases of uterine leiomyosarcoma, and 1 case of endometrial stromal sarcoma. Comparisons between the pulmonary metastasectomy group (11 cases) and the non-surgical group (24 cases) showed statistically significant differences in the number of pulmonary metastases (≤3 cm and >3 cm), presence of extrapulmonary metastases, and disease-free interval (P<0.05). Follow-up ranged from 5 to 107 months. The median post-lung-metastases overall survival (PLM-OS) was 32.4 months in the surgical group versus 28.5 months in the non-surgical group (P=0.812); the median post-lung-metastases progression-free survival (PLM-PFS) was 16.5 months and 14.1 months, respectively (P=0.740). Univariate Cox regression analysis identified histologic type as a prognostic factor for PLM-PFS (P=0.025); patients with endometrial carcinoma pulmonary metastases had better PLM-PFS than those with endometrial stromal sarcoma/leiomyosarcoma (HR=4.716, 95% CI: 0.151-0.941, P=0.037). Conclusions Prognosis of uterine malignancy patients with pulmonary metastases is associated with the primary tumor histologic type. For patients with ≤3 pulmonary metastases, no extrapulmonary disease, and a recurrence-free interval greater than 12 months, pulmonary metastasectomy may be considered under strict surgical indications, but larger studies are warranted.
  • TIAN LI, WANG Jianliu.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 97-98. https://doi.org/10.13390/j.issn.1672-1861.2026.02.001
  • XU Xiaolin, WANG Hui, XU Zijuan, YU Shuqin.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(3): 208-210. https://doi.org/10.13390/j.issn.1672-1861.2026.03.005
    Objective To compare the application effects of interrupted suture and heart-shaped tension-reducing suture for abdominal wall incision in cesarean section with scarred uterus. Methods A total of 108 with scarred uterus who received cesarean section in the hospital were selected from January 2023 to December 2024. According to the different surgical suture methods, they were divided into conventional group (conventional interrupted suture, 52 cases) and study group (heart-shaped tension-reducing suture, 56 cases). The surgery-related indicators, pain status, incision healing status, scar conditions and occurrence of adverse reactions were compared between the two groups of patients. Results The incision suture time and incision healing time of patients in study group were shorter than those in conventional group (P<0.05). The Visual Analogue Scale (VAS) score in both groups was gradually decreased at 3, 5 and 7 days after surgery compared with that at 1 day after surgery, and the score in study group was lower than that in conventional group (P<0.05). At 7 days after surgery, the incision healing status in study group was better than that in conventional group (P<0.05). The Vancouver Scar Scale (VSS) score, width of the widest scar and thickness of protruded skin in study group at 6 weeks of follow-up after surgery were lower than those in conventional group (P<0.05). The incidence of adverse reactions in study group was lower compared to conventional group (P<0.05). Conclusion Compared with interrupted suture, abdominal wall incision heart-shaped tension-reducing suture during cesarean section of scarred uterus can more effectively shorten the incision suture time and healing time of patients.
  • WU Yan, OU-YANG Jianghua, WU Yanli, TANG Mengdong, GAO Yongmei.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 26-29.
    Objective To investigate the influence of adjustment of adjuvant chemotherapy dose on the prognosis in elderly patients with advanced ovarian cancer comorbidities. Methods The clinical data of elderly patients with advanced ovarian cancer comorbidities who were initially treated in department of gynecological oncology of Qingdao Hospital of Traditional Chinese Medicine were retrospectively analyzed from January 2016 to January 2019. All patients received initial cytoreductive surgery, and started adjuvant chemotherapy (platinum-based first-line chemotherapy regimen) at 7~21 days after surgery. According to whether the chemotherapy dose was adjusted, the patients were divided into full dose group (n=50) and chemotherapy dose adjustment group (n=52). The clinical efficacy, serum tumor markers [carbohydrate antigen 125 (CA125) and human epididymis secretory protein 4 (HE4)] and occurrence of adverse reactions were compared between groups. The patients in both groups were followed up, and the survival curve was drawn by Kaplan-Meier method. The prognosis and survival of the two groups were observed and compared. Results There were no obvious differences in ORR and DCR between the chemotherapy dose adjustment group and the full dose group (P>0.05). After the end of treatment, serum levels of CA125 and HE4 in both groups were decreased (P<0.05), while the difference between groups was not significant (P>0.05). The incidence rates of gradeⅢ~Ⅳgastrointestinal reactions and gradeⅢ~Ⅳanemia were lower than those in the full dose group (P<0.05). The progression-free survival (PFS) and overall survival (OS) were no significant difference between the chemotherapy dose adjustment group and the full dose group (P>0.05). Conclusions Compared with the full dose of chemotherapy, adjuvant chemotherapy dose adjustment for elderly patients with advanced ovarian cancer comorbidities can relieve the adverse reactions and will not affect the clinical efficacy and prognosis of patients.
  • Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(1): 86-88. https://doi.org/10.13390/j.issn.1672-1861.2026.01.029
    外泌体作为细胞间通讯的重要媒介,通过携带蛋白质、脂质、DNA、mRNA和非编码RNA等生物活性分子,参与体液循环,在各细胞信息沟通过程中发挥着重要功能。越来越多的研究证实,外泌体在子宫内膜癌(endometrial cancer, EC)的增殖、转移及微环境调控中起着关键作用,有望成为新型生物标志物及治疗新靶点,具有重要的研究价值。本文综述了外泌体在EC诊断和治疗中的最新研究进展,以期为EC患者带来新的希冀。
  • WEI Shiyao, PENG Shuyi, AN Xiaofei.
    Chinese Journal of Clinical Obstetrics and Gynecology. 2026, 27(2): 143-146. https://doi.org/10.13390/j.issn.1672-1861.2026.02.011
     To identify clinical subtype characteristics of polycystic ovary syndrome (PCOS) via cluster analysis, and provide novel evidence for individualized diagnosis and treatment. Methods This retrospective study enrolled 522 reproductive-aged (20-45 years old) PCOS patients from the Endocrinology Clinic of the Affiliated Hospital of Nanjing University of Chinese Medicine from March 2022 to September 2025, collecting their clinical characteristics, sex hormone levels and metabolic indicators. Patients were divided by oligomenorrhea severity and blood sampling time into mild (menstrual cycle 36-90 d, n=229) and severe oligomenorrhea groups (91-180 d, n=293). K-means cluster analysis was performed for body mass index, homeostasis model assessment of insulin resistance, free androgen index and luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio. Intergroup differences in clinical indicators were analyzed. Results Four distinct subtypes were identified in two groups. In the mild group: Subtype A (21.8%, 50/229) featured oligomenorrhea and polycystic ovarian morphology without obesity, insulin resistance (IR) or hyperandrogenemia (HA); Subtype B (29.7%, 68/229) had LH/FSH≥2 (mild HA optional) without obesity or IR; Subtypes C (27.5%, 63/229) and D (21.0%, 48/229) both had obesity, IR and HA, but the LH/FSH ratio of Subtype C approached 1, and Subtype D LH/FSH≥2. The core clinical features of each subtype in the severe oligomenorrhea group were basically consistent with those in the mild oligomenorrhea group. Conclusions PCOS patients can be classified into four distinct subtypes. This novel classification guides investigations into PCOS pathophysiological mechanisms and promotes individualized clinical treatment.